Sath Nirmalananthan, the CFO of Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF), presented an overview of the company and its advancements in immunotherapy at the Proactive One2One Investor Forum. Scancell, a clinical-stage company, focuses on developing cancer vaccines and antibodies, with its lead asset being a cancer vaccine called SCIB1 for advanced melanoma. SCIB1 has shown promising monotherapy data and combination data with double checkpoint inhibitors. The company anticipates key milestones in 2024, including further clinical data readouts.
Scancell's innovative approach involves the development of non-personalised, off-the-shelf cancer vaccines, contrasting with the personalised vaccines by competitors like Moderna and BioNTech. SCIB1 targets antigen-presenting cells in vivo, generating potent T-cell responses, and is administered using a needle-free device. This vaccine has demonstrated low toxicity and compelling efficacy.
Scancell is also working on SCIB1+, a next-generation vaccine with broader applicability, expected to recruit faster and cover a larger patient population. The company's pipeline includes multiple assets derived from four platforms: ImmunoBody, Moditope, GlyMab, and AvidiMab. The development of SCIB1 and SCIB1+ is on track, with significant data readouts anticipated in late 2024 and early 2025.
Funding remains a focus, with recent capital raised and potential for additional non-dilutive funding through antibody licensing. Scancell aims to continue advancing its clinical trials and is exploring strategic options to ensure the best outcomes for shareholders.